Nanodiamond-Protein hybrid Nanoparticles: LHRH receptor targeted and co-delivery of doxorubicin and dasatinib for triple negative breast cancer therapy

Keywords

Protein nanoparticle

Nanodiamond

Triple-negative breast cancer

Targeted combined therapy

Synergistic delivery

Chemical compounds studied in this article

Doxorubicin Hydrochloride (PubChem CID: 443939)

Dasatinib (PubChem CID: 3062316)

polyethyleneimine 1200 MW (PubChem CID: 9033)

(3-Aminopropyl)triethoxysilane (PubChem CID: 13521)

poly (ethylene glycol) (PEG*** 1000 Da) (CAS number: 25322-68-3)

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (PubChem CID: 18329082)

N Hydroxysulfosuccinimide (sulfo-NHS) (PubChem CID: 3520574)

Data availability

Data will be made available on request.

View original article

0 0 0 0 0 0 0

Comments (0)